JPWO2020060299A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020060299A5 JPWO2020060299A5 JP2021516367A JP2021516367A JPWO2020060299A5 JP WO2020060299 A5 JPWO2020060299 A5 JP WO2020060299A5 JP 2021516367 A JP2021516367 A JP 2021516367A JP 2021516367 A JP2021516367 A JP 2021516367A JP WO2020060299 A5 JPWO2020060299 A5 JP WO2020060299A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- oxadiazol
- methyl
- ethanol
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 18
- 230000003287 optical effect Effects 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000005221 halo alkyl carbonyl amino group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- YNKVQXSDCYNFAS-CYBMUJFWSA-N (1R)-1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)OCCCC(F)(F)F)[C@@H](CC=1OC(=NN=1)C)O YNKVQXSDCYNFAS-CYBMUJFWSA-N 0.000 claims 1
- XDIMTQVLBINEQV-MRXNPFEDSA-N (1R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound CC1=NN=C(O1)C[C@@H](O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F XDIMTQVLBINEQV-MRXNPFEDSA-N 0.000 claims 1
- YNKVQXSDCYNFAS-ZDUSSCGKSA-N (1S)-1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)OCCCC(F)(F)F)[C@H](CC=1OC(=NN=1)C)O YNKVQXSDCYNFAS-ZDUSSCGKSA-N 0.000 claims 1
- XDIMTQVLBINEQV-INIZCTEOSA-N (1S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound CC1=NN=C(O1)C[C@H](O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F XDIMTQVLBINEQV-INIZCTEOSA-N 0.000 claims 1
- SGPJMAHDAZQWNJ-UHFFFAOYSA-N 1-(2-fluoro-5-pentylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCCCC)C(CC=1OC(=NN=1)C)O SGPJMAHDAZQWNJ-UHFFFAOYSA-N 0.000 claims 1
- CGFWCAKELWFMFQ-UHFFFAOYSA-N 1-(2-fluoro-5-propylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCC)C(CC=1OC(=NN=1)C)O CGFWCAKELWFMFQ-UHFFFAOYSA-N 0.000 claims 1
- JFPBNQPZHCGAHS-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound C(CCC)OC=1C=CC(=C(C=1)C(CC=1OC(=NN=1)C)O)F JFPBNQPZHCGAHS-UHFFFAOYSA-N 0.000 claims 1
- GTUQNUNHXPHWLS-UHFFFAOYSA-N 1-[2-chloro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=C(C=C(C=C1)OCCCC(F)(F)F)C(CC=1OC(=NN=1)C)O GTUQNUNHXPHWLS-UHFFFAOYSA-N 0.000 claims 1
- XXPOYKSDYFDKGX-UHFFFAOYSA-N 1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=C(C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(CC=1OC=NN=1)O XXPOYKSDYFDKGX-UHFFFAOYSA-N 0.000 claims 1
- OGYWLTKONULRFE-UHFFFAOYSA-N 1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=C(C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(CC=1OC(=NN=1)C)O OGYWLTKONULRFE-UHFFFAOYSA-N 0.000 claims 1
- VEHNPOVFEDOWAP-UHFFFAOYSA-N 1-[2-fluoro-5-(2,2,2-trifluoroethoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)OCC(F)(F)F)C(CC=1OC(=NN=1)C)O VEHNPOVFEDOWAP-UHFFFAOYSA-N 0.000 claims 1
- CDSMLHOEOQZHIS-UHFFFAOYSA-N 1-[2-fluoro-5-(3,3,3-trifluoropropyl)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCC(F)(F)F)C(CC=1OC=NN=1)O CDSMLHOEOQZHIS-UHFFFAOYSA-N 0.000 claims 1
- FVNPKRIBCSEBGV-UHFFFAOYSA-N 1-[2-fluoro-5-(3,3,3-trifluoropropyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCC(F)(F)F)C(CC=1OC(=NN=1)C)O FVNPKRIBCSEBGV-UHFFFAOYSA-N 0.000 claims 1
- XGAXODJRTRBIDD-UHFFFAOYSA-N 1-[2-fluoro-5-(3-piperidin-1-ylpropoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)OCCCN1CCCCC1)C(CC=1OC(=NN=1)C)O XGAXODJRTRBIDD-UHFFFAOYSA-N 0.000 claims 1
- LASGMYVHCOEJPO-UHFFFAOYSA-N 1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)OCCCC(F)(F)F)C(CC=1OC=NN=1)O LASGMYVHCOEJPO-UHFFFAOYSA-N 0.000 claims 1
- YNKVQXSDCYNFAS-UHFFFAOYSA-N 1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)OCCCC(F)(F)F)C(CC=1OC(=NN=1)C)O YNKVQXSDCYNFAS-UHFFFAOYSA-N 0.000 claims 1
- RFBHKRWKDPPGHX-UHFFFAOYSA-N 1-[2-fluoro-5-(4,4,4-trifluorobutyl)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCCC(F)(F)F)C(CC=1OC=NN=1)O RFBHKRWKDPPGHX-UHFFFAOYSA-N 0.000 claims 1
- KYFNUDPJNPMPBK-UHFFFAOYSA-N 1-[2-fluoro-5-(4,4,4-trifluorobutyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCCC(F)(F)F)C(CC=1OC(=NN=1)C)O KYFNUDPJNPMPBK-UHFFFAOYSA-N 0.000 claims 1
- VGGSLVCOMAMNAD-UHFFFAOYSA-N 1-[2-fluoro-5-(5,5,5-trifluoropentyl)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCCCC(F)(F)F)C(CC=1OC=NN=1)O VGGSLVCOMAMNAD-UHFFFAOYSA-N 0.000 claims 1
- HYHXIIPCGHOXJX-UHFFFAOYSA-N 1-[2-fluoro-5-(5,5,5-trifluoropentyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)CCCCC(F)(F)F)C(CC=1OC(=NN=1)C)O HYHXIIPCGHOXJX-UHFFFAOYSA-N 0.000 claims 1
- LGIPLJAQKAVCNM-UHFFFAOYSA-N 1-[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(CC=1OC=NN=1)O LGIPLJAQKAVCNM-UHFFFAOYSA-N 0.000 claims 1
- PUCICUYQKUAICC-UHFFFAOYSA-N 1-[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=C(C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(CC=1OC(=NN=1)C)O PUCICUYQKUAICC-UHFFFAOYSA-N 0.000 claims 1
- YJBDDOBMJJFJQD-UHFFFAOYSA-N 1-[2-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound COC1=C(C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(CC=1OC=NN=1)O YJBDDOBMJJFJQD-UHFFFAOYSA-N 0.000 claims 1
- MMPYTDJMJUOWEG-UHFFFAOYSA-N 1-[2-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound COC1=C(C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(CC=1OC(=NN=1)C)O MMPYTDJMJUOWEG-UHFFFAOYSA-N 0.000 claims 1
- CFKWVMQTSOWYGE-UHFFFAOYSA-N 1-[2-methyl-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol Chemical compound CC1=C(C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(CC=1OC=NN=1)O CFKWVMQTSOWYGE-UHFFFAOYSA-N 0.000 claims 1
- XPSLTNDOKZBAHS-UHFFFAOYSA-N 1-[3-(2-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=C(C=CC=C1)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O XPSLTNDOKZBAHS-UHFFFAOYSA-N 0.000 claims 1
- UKPXGJDTDHKASN-UHFFFAOYSA-N 1-[3-(3,4-difluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC=1C=C(C=CC=1F)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O UKPXGJDTDHKASN-UHFFFAOYSA-N 0.000 claims 1
- SCMXTRNIEAKUDA-UHFFFAOYSA-N 1-[3-(3-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC=1C=C(C=CC=1)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O SCMXTRNIEAKUDA-UHFFFAOYSA-N 0.000 claims 1
- CXYSPVXHWKYSDV-UHFFFAOYSA-N 1-[3-(4-chloro-2-methoxyphenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=CC(=C(C=C1)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O)OC CXYSPVXHWKYSDV-UHFFFAOYSA-N 0.000 claims 1
- GPOMQDAZVBLDLO-UHFFFAOYSA-N 1-[3-(4-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=CC=C(C=C1)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O GPOMQDAZVBLDLO-UHFFFAOYSA-N 0.000 claims 1
- KJVQBYGGGNJFFL-UHFFFAOYSA-N 1-[3-(4-fluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound FC1=CC=C(C=C1)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O KJVQBYGGGNJFFL-UHFFFAOYSA-N 0.000 claims 1
- XOHVMEFPLARJEI-UHFFFAOYSA-N 1-[3-[2,4-bis(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound CC1=NN=C(CC(O)C2=CC(=CC=C2)C2=CC=C(C=C2C(F)(F)F)C(F)(F)F)O1 XOHVMEFPLARJEI-UHFFFAOYSA-N 0.000 claims 1
- PKRVNYPQBLJBCS-UHFFFAOYSA-N 1-[3-[2-methoxy-4-(trifluoromethoxy)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound COC1=C(C=CC(=C1)OC(F)(F)F)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O PKRVNYPQBLJBCS-UHFFFAOYSA-N 0.000 claims 1
- QXLIKZKFYILPFT-UHFFFAOYSA-N 1-[3-[4-chloro-2-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=CC(=C(C=C1)C=1C=C(C=CC=1)C(CC=1OC(=NN=1)C)O)C(F)(F)F QXLIKZKFYILPFT-UHFFFAOYSA-N 0.000 claims 1
- NCMZXXAEWRRPHQ-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-2-fluorophenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound ClC1=CC=C(C=C1)C=1C=CC(=C(C=1)C(CC=1OC(=NN=1)C)O)F NCMZXXAEWRRPHQ-UHFFFAOYSA-N 0.000 claims 1
- JQKOFZBYYLMBPE-UHFFFAOYSA-N 1-[5-[3-(dimethylamino)propoxy]-2-fluorophenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol Chemical compound CN(CCCOC=1C=CC(=C(C=1)C(CC=1OC(=NN=1)C)O)F)C JQKOFZBYYLMBPE-UHFFFAOYSA-N 0.000 claims 1
- VPJNYEBHWWJJCY-UHFFFAOYSA-N 2-(1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound O1C(=NN=C1)CC(O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F VPJNYEBHWWJJCY-UHFFFAOYSA-N 0.000 claims 1
- DDNLNNBGYHGNNR-UHFFFAOYSA-N 2-(3-methyl-1,2,4-oxadiazol-5-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound CC1=NOC(=N1)CC(O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F DDNLNNBGYHGNNR-UHFFFAOYSA-N 0.000 claims 1
- DZQJDPDAGLNNSB-UHFFFAOYSA-N 2-(5-ethyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound C(C)C1=NN=C(O1)CC(O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F DZQJDPDAGLNNSB-UHFFFAOYSA-N 0.000 claims 1
- JXGKEBOPNJDVDC-UHFFFAOYSA-N 2-(5-methyl-1,2,4-oxadiazol-3-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound CC1=NC(=NO1)CC(O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F JXGKEBOPNJDVDC-UHFFFAOYSA-N 0.000 claims 1
- GUFPGCNOAMYEMC-UHFFFAOYSA-N 2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[2-methyl-5-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound CC1=NN=C(O1)CC(O)C1=C(C=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C GUFPGCNOAMYEMC-UHFFFAOYSA-N 0.000 claims 1
- MYBPYPWJCHGCEB-UHFFFAOYSA-N 2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(2,2,3,3-tetrafluoropropoxy)phenyl]ethanol Chemical compound CC1=NN=C(O1)CC(O)C1=CC(=CC=C1)OCC(C(F)F)(F)F MYBPYPWJCHGCEB-UHFFFAOYSA-N 0.000 claims 1
- VQSGRXPSFXHVNT-UHFFFAOYSA-N 2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethanol Chemical compound CC1=NN=C(O1)CC(O)C1=CC(=CC=C1)OCCCC(F)(F)F VQSGRXPSFXHVNT-UHFFFAOYSA-N 0.000 claims 1
- VXOAINQTFDJCSO-UHFFFAOYSA-N 2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]propan-1-ol Chemical compound CC1=NN=C(O1)C(C(O)C1=CC(=CC=C1)OCCCC(F)(F)F)C VXOAINQTFDJCSO-UHFFFAOYSA-N 0.000 claims 1
- VZAJVJBNDULTMM-UHFFFAOYSA-N 2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethoxy)phenyl]phenyl]ethanol Chemical compound CC1=NN=C(O1)CC(O)C1=CC(=CC=C1)C1=CC=C(C=C1)OC(F)(F)F VZAJVJBNDULTMM-UHFFFAOYSA-N 0.000 claims 1
- XDIMTQVLBINEQV-UHFFFAOYSA-N 2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound CC1=NN=C(O1)CC(O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F XDIMTQVLBINEQV-UHFFFAOYSA-N 0.000 claims 1
- ADBULDCZLAOVAN-UHFFFAOYSA-N 2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol Chemical compound C(C)(C)(C)C1=NN=C(O1)CC(O)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F ADBULDCZLAOVAN-UHFFFAOYSA-N 0.000 claims 1
- DNZLECYKVXNCLV-UHFFFAOYSA-N 2-[2-methoxy-2-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl]-5-methyl-1,3,4-oxadiazole Chemical compound COC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F DNZLECYKVXNCLV-UHFFFAOYSA-N 0.000 claims 1
- HSWFYJVFAMJBHK-UHFFFAOYSA-N 2-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethanol Chemical compound FC(C(O)C1=CC(=CC=C1)OCCCC(F)(F)F)C=1OC(=NN=1)C HSWFYJVFAMJBHK-UHFFFAOYSA-N 0.000 claims 1
- USFSCYZSUSYJMT-UHFFFAOYSA-N 4-fluoro-3-[1-hydroxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-N-(3,3,3-trifluoropropyl)benzamide Chemical compound FC1=C(C=C(C(=O)NCCC(F)(F)F)C=C1)C(CC=1OC(=NN=1)C)O USFSCYZSUSYJMT-UHFFFAOYSA-N 0.000 claims 1
- SJJXIJWRWXWYMM-UHFFFAOYSA-N C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)OCCCC(F)(F)F)Cl)=O Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)OCCCC(F)(F)F)Cl)=O SJJXIJWRWXWYMM-UHFFFAOYSA-N 0.000 claims 1
- VPLKYVPLFWMDDN-UHFFFAOYSA-N CC1=NN=C(O1)CC(C2=CC=CC(=C2)C3=CC=C(C=C3)OC(F)(F)F)NC(=O)O Chemical compound CC1=NN=C(O1)CC(C2=CC=CC(=C2)C3=CC=C(C=C3)OC(F)(F)F)NC(=O)O VPLKYVPLFWMDDN-UHFFFAOYSA-N 0.000 claims 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 claims 1
- YQRNIGRMNXQZMD-UHFFFAOYSA-N [1-(2-fluoro-5-pentylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)CCCCC)F)=O YQRNIGRMNXQZMD-UHFFFAOYSA-N 0.000 claims 1
- XLMYFIIHZGJBSN-UHFFFAOYSA-N [1-(2-fluoro-5-propylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)CCC)F)=O XLMYFIIHZGJBSN-UHFFFAOYSA-N 0.000 claims 1
- QKVYLFPNZWHZBX-UHFFFAOYSA-N [1-(5-butoxy-2-fluorophenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)OCCCC)F)=O QKVYLFPNZWHZBX-UHFFFAOYSA-N 0.000 claims 1
- PJMBHGINCWDQOS-UHFFFAOYSA-N [1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC=NN=1)C1=C(C=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)Cl)=O PJMBHGINCWDQOS-UHFFFAOYSA-N 0.000 claims 1
- IPIXGEUNUXQCLO-UHFFFAOYSA-N [1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)Cl)=O IPIXGEUNUXQCLO-UHFFFAOYSA-N 0.000 claims 1
- QIZJMYUFIXUJSI-UHFFFAOYSA-N [1-[2-fluoro-5-(2,2,2-trifluoroethoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)OCC(F)(F)F)F)=O QIZJMYUFIXUJSI-UHFFFAOYSA-N 0.000 claims 1
- MXRHNXVEHMAKCL-UHFFFAOYSA-N [1-[2-fluoro-5-(3,3,3-trifluoropropyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)CCC(F)(F)F)F)=O MXRHNXVEHMAKCL-UHFFFAOYSA-N 0.000 claims 1
- BXRYFFDILBIBNE-UHFFFAOYSA-N [1-[2-fluoro-5-(3,3,3-trifluoropropylcarbamoyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)C(NCCC(F)(F)F)=O)F)=O BXRYFFDILBIBNE-UHFFFAOYSA-N 0.000 claims 1
- NLYRWYWIIUMPKB-UHFFFAOYSA-N [1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC=NN=1)C1=C(C=CC(=C1)OCCCC(F)(F)F)F)=O NLYRWYWIIUMPKB-UHFFFAOYSA-N 0.000 claims 1
- IGLDJOTUFGRUAB-UHFFFAOYSA-N [1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)OCCCC(F)(F)F)F)=O IGLDJOTUFGRUAB-UHFFFAOYSA-N 0.000 claims 1
- YXVBUBBEDKBZBU-UHFFFAOYSA-N [1-[2-fluoro-5-(4,4,4-trifluorobutyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)CCCC(F)(F)F)F)=O YXVBUBBEDKBZBU-UHFFFAOYSA-N 0.000 claims 1
- YRCPAOOFJOAWBD-UHFFFAOYSA-N [1-[2-fluoro-5-(5,5,5-trifluoropentyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)CCCCC(F)(F)F)F)=O YRCPAOOFJOAWBD-UHFFFAOYSA-N 0.000 claims 1
- PBLBHRDJLMHAMH-UHFFFAOYSA-N [1-[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)F)=O PBLBHRDJLMHAMH-UHFFFAOYSA-N 0.000 claims 1
- HXZDWKOGQJOQST-UHFFFAOYSA-N [1-[2-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)OC)=O HXZDWKOGQJOQST-UHFFFAOYSA-N 0.000 claims 1
- LRJOSPODESICHN-UHFFFAOYSA-N [1-[3-(3,4-difluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=CC(=C(C=C1)F)F)=O LRJOSPODESICHN-UHFFFAOYSA-N 0.000 claims 1
- WGJUKAIQYSEHOD-UHFFFAOYSA-N [1-[3-(3-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=CC(=CC=C1)Cl)=O WGJUKAIQYSEHOD-UHFFFAOYSA-N 0.000 claims 1
- MDEPYLQZNAWVSS-UHFFFAOYSA-N [1-[3-(4-chloro-2-methoxyphenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=C(C=C(C=C1)Cl)OC)=O MDEPYLQZNAWVSS-UHFFFAOYSA-N 0.000 claims 1
- NXGLGIJFZBXBSF-UHFFFAOYSA-N [1-[3-(4-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=CC=C(C=C1)Cl)=O NXGLGIJFZBXBSF-UHFFFAOYSA-N 0.000 claims 1
- LPLPPTNRUWYYLT-UHFFFAOYSA-N [1-[3-(4-fluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=CC=C(C=C1)F)=O LPLPPTNRUWYYLT-UHFFFAOYSA-N 0.000 claims 1
- AMQFCGNJTUUKOG-UHFFFAOYSA-N [1-[3-[2,4-bis(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=C(C=C(C=C1)C(F)(F)F)C(F)(F)F)=O AMQFCGNJTUUKOG-UHFFFAOYSA-N 0.000 claims 1
- RDSBGCPKKPWZBD-UHFFFAOYSA-N [1-[3-[2-methoxy-4-(trifluoromethoxy)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=C(C=C(C=C1)OC(F)(F)F)OC)=O RDSBGCPKKPWZBD-UHFFFAOYSA-N 0.000 claims 1
- FRJMEYPWTPQRKV-UHFFFAOYSA-N [1-[3-[4-chloro-2-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=C(C=C(C=C1)Cl)C(F)(F)F)=O FRJMEYPWTPQRKV-UHFFFAOYSA-N 0.000 claims 1
- FMKHAWCALAEDJK-UHFFFAOYSA-N [1-[5-(4-chlorophenyl)-2-fluorophenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)C1=CC=C(C=C1)Cl)F)=O FMKHAWCALAEDJK-UHFFFAOYSA-N 0.000 claims 1
- QTAFCQXXMFVJPS-UHFFFAOYSA-N [1-[5-[3-(dimethylamino)propoxy]-2-fluorophenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)OCCCN(C)C)F)=O QTAFCQXXMFVJPS-UHFFFAOYSA-N 0.000 claims 1
- CISPBQNURGNYQD-UHFFFAOYSA-N [2-(3-methyl-1,2,4-oxadiazol-5-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl] carbamate Chemical compound C(N)(OC(CC1=NC(=NO1)C)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F)=O CISPBQNURGNYQD-UHFFFAOYSA-N 0.000 claims 1
- HOLPTEWXCDYHOB-UHFFFAOYSA-N [2-(5-methyl-1,2,4-oxadiazol-3-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl] carbamate Chemical compound C(N)(OC(CC1=NOC(=N1)C)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F)=O HOLPTEWXCDYHOB-UHFFFAOYSA-N 0.000 claims 1
- HKBPLWYRVXEARV-UHFFFAOYSA-N [2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[2-methyl-5-[4-(trifluoromethyl)phenyl]phenyl]ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=C(C=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C)=O HKBPLWYRVXEARV-UHFFFAOYSA-N 0.000 claims 1
- LTYFZMUHRLKBMU-UHFFFAOYSA-N [2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(2,2,3,3-tetrafluoropropoxy)phenyl]ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)OCC(C(F)F)(F)F)=O LTYFZMUHRLKBMU-UHFFFAOYSA-N 0.000 claims 1
- FUJVKZVRBQTBQZ-UHFFFAOYSA-N [2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)OCCCC(F)(F)F)=O FUJVKZVRBQTBQZ-UHFFFAOYSA-N 0.000 claims 1
- IXOLEGJOYWFJHE-UHFFFAOYSA-N [2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]propyl] carbamate Chemical compound C(N)(OC(C(C)C=1OC(=NN=1)C)C1=CC(=CC=C1)OCCCC(F)(F)F)=O IXOLEGJOYWFJHE-UHFFFAOYSA-N 0.000 claims 1
- AGDGEJNUEMOMFB-UHFFFAOYSA-N [2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl] acetate Chemical compound C(C)(=O)OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F AGDGEJNUEMOMFB-UHFFFAOYSA-N 0.000 claims 1
- DVADAJWTUNWDKD-UHFFFAOYSA-N [2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl] carbamate Chemical compound C(N)(OC(CC=1OC(=NN=1)C)C1=CC(=CC=C1)C1=CC=C(C=C1)C(F)(F)F)=O DVADAJWTUNWDKD-UHFFFAOYSA-N 0.000 claims 1
- ATRLEYJBCZQLTR-UHFFFAOYSA-N [2-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl] carbamate Chemical compound C(N)(OC(C(C=1OC(=NN=1)C)F)C1=CC(=CC=C1)OCCCC(F)(F)F)=O ATRLEYJBCZQLTR-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 carbamoyloxy Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Claims (17)
[式中、R1は、下記構造式
からなる群から選ばれ、
R2は、水素、ハロ、ヒドロキシ、アルキル、ハロアルキル、ヒドロキシアルキル、アルコキシアルキル、カルバモイルオキシ、アルコキシ、アルキルチオ、ハロアルコキシ、又はヒドロキシアルコキシであり、
R3は、水素、アルキル、シクロアルキル、ハロアルキル、ヒドロキシアルキル、アルコキシアルキル、カルバモイル、アルキルカルバモイル、ジアルキルカルバモイル、カルボニル、又はアルキルカルボニルであり、
R4は、水素、ハロ、ヒドロキシ、アルキル、ハロアルキル、ヒドロキシアルキル、アルコキシアルキル、カルバモイル、アルキルカルバモイル、又はジアルキルカルバモイルであり、
R5は、水素、ハロ、ヒドロキシ、アルキル、ハロアルキル、ヒドロキシアルキル、アルコキシアルキル、カルバモイル、アルキルカルバモイル、又はジアルキルカルバモイルであり、
X、Y、Zは、それぞれ独立して、窒素(N)及び酸素(O)からなる群から選ばれ、このとき、X、Y又はZの少なくとも一つは、酸素(O)であり、
qは、0~2の整数である]
で示される化合物、又はその光学異性体、立体異性体又は薬学的に許容される塩。 Formula (1) below
[In the formula, R1 is the following structural formula
selected from the group consisting of
R2 is hydrogen, halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, carbamoyloxy, alkoxy, alkylthio, haloalkoxy, or hydroxyalkoxy;
R3 is hydrogen, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, carbonyl, or alkylcarbonyl;
R4 is hydrogen, halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, carbamoyl, alkylcarbamoyl, or dialkylcarbamoyl;
R5 is hydrogen, halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, carbamoyl, alkylcarbamoyl, or dialkylcarbamoyl;
X, Y and Z are each independently selected from the group consisting of nitrogen (N) and oxygen (O), wherein at least one of X, Y or Z is oxygen (O);
q is an integer from 0 to 2]
A compound represented by or an optical isomer, stereoisomer or pharmaceutically acceptable salt thereof.
からなる群から選ばれ、
R2が、水素、ハロ、アルキル、ハロアルキル、ヒドロキシアルキル、アルコキシアルキル、アルコキシ、アルキルチオ、ハロアルコキシ、又はヒドロキシアルコキシであり、
R3が、水素、アルキル、シクロアルキル、ハロアルキル、アルコキシアルキル、カルバモイル、アルキルカルバモイル、ジアルキルカルバモイル、カルボニル、又はアルキルカルボニルであり、
R4が、水素、ハロ、アルキル、ハロアルキル、アルコキシアルキル、カルバモイル、アルキルカルバモイル、又はジアルキルカルバモイルであり、
R5が、水素、ハロ、アルキル、ハロアルキル、アルコキシアルキル、カルバモイル、アルキルカルバモイル、又はジアルキルカルバモイルであり、
X、Y、Zが、それぞれ独立して、窒素(N)及び酸素(O)からなる群から選ばれ、このとき、X、Y又はZの一つは、酸素(O)であり、残りの二つは窒素(N)であり、
qが、0~2の整数である、請求項1に記載の化合物、又はその光学異性体、立体異性体又は薬学的に許容される塩。 R1 is the following structural formula
selected from the group consisting of
R2 is hydrogen, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, alkylthio, haloalkoxy, or hydroxyalkoxy;
R3 is hydrogen, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, carbonyl, or alkylcarbonyl;
R4 is hydrogen, halo, alkyl, haloalkyl, alkoxyalkyl, carbamoyl, alkylcarbamoyl, or dialkylcarbamoyl;
R5 is hydrogen, halo, alkyl, haloalkyl, alkoxyalkyl, carbamoyl, alkylcarbamoyl, or dialkylcarbamoyl;
X, Y and Z are each independently selected from the group consisting of nitrogen (N) and oxygen (O), wherein one of X, Y or Z is oxygen (O) and the remaining two are nitrogen (N),
The compound according to claim 1, or an optical isomer, stereoisomer or pharmaceutically acceptable salt thereof, wherein q is an integer of 0-2.
からなる群から選ばれ、
R2が、水素、ハロ、アルキル、ハロアルキル、アルコキシアルキル、アルコキシ、又はアルキルチオであり、
R3が、水素、アルキル、シクロアルキル、ハロアルキル、カルバモイル、アルキルカルバモイル、ジアルキルカルバモイル、又はカルボニルであり、
R4が、水素、ハロ、アルキル、ハロアルキル、又はアルコキシアルキルであり、
R5が、水素、ハロ、アルキル、ハロアルキル、又はアルコキシアルキルであり、
X、Y、Zが、それぞれ独立して、窒素(N)及び酸素(O)からなる群から選ばれ、このとき、X、Y又はZの一つは、酸素(O)であり、残りの二つは窒素(N)であり、
qが、0~2の整数である、請求項2に記載の化合物、又はその光学異性体、立体異性体又は薬学的に許容される塩。 R1 is the following structural formula
selected from the group consisting of
R2 is hydrogen, halo, alkyl, haloalkyl, alkoxyalkyl, alkoxy, or alkylthio;
R3 is hydrogen, alkyl, cycloalkyl, haloalkyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, or carbonyl;
R4 is hydrogen, halo, alkyl, haloalkyl, or alkoxyalkyl;
R5 is hydrogen, halo, alkyl, haloalkyl, or alkoxyalkyl;
X, Y and Z are each independently selected from the group consisting of nitrogen (N) and oxygen (O), wherein one of X, Y or Z is oxygen (O) and the remaining two are nitrogen (N),
3. The compound according to claim 2, or an optical isomer, stereoisomer or pharmaceutically acceptable salt thereof, wherein q is an integer from 0 to 2.
R3が、水素、アルキル又はカルバモイルであり、
R4が、水素、ハロ又はアルキルであり、
R5が、水素又はアルキルである、請求項1に記載の化合物、その光学異性体、立体異性体又は薬学的に許容される塩。 R2 is hydrogen, halo, alkyl or alkoxy;
R3 is hydrogen, alkyl or carbamoyl;
R4 is hydrogen, halo or alkyl;
3. The compound of claim 1, an optical isomer, stereoisomer or pharmaceutically acceptable salt thereof, wherein R5 is hydrogen or alkyl.
n、o及びpが、それぞれ独立して、1~4の整数であり、
qが、0又は1の整数である、請求項6に記載の化合物、その光学異性体、立体異性体又は薬学的に許容される塩。 m is an integer of 1 or 2,
n, o and p are each independently an integer of 1 to 4;
7. The compound, optical isomer, stereoisomer or pharmaceutically acceptable salt thereof according to claim 6, wherein q is an integer of 0 or 1.
1-[5-(4-クロロフェニル)-2-フルオロ-フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-フルオロ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[2-フルオロ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[5-(4-クロロフェニル)-2-フルオロ-フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[2-フルオロ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エチル]カルバメート;
(1R)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
(1S)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[2-メチル-5-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
1-[2-メトキシ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[2-メチル-5-[4-(トリフルオロメチル)フェニル]フェニル]エチル]カルバメート;
[1-[2-メトキシ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[2-メチル-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-メトキシ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-クロロ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-クロロ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[2-クロロ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[2-クロロ-5-[4-(トリフルオロメチル)フェニル]フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
2-(1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
2-(5-エチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
2-(5-t-ブチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エチル]アセテート;
2-[2-メトキシ-2-[3-[4-(トリフルオロメチル)フェニル]フェニル]エチル]-5-メチル-1,3,4-オキサジアゾール;
1-[3-(4-フルオロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[3-(3,4-ジフルオロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-[4-(トリフルオロメトキシ)フェニル]フェニル]エタノール;
1-[3-(2-メトキシ-4-(トリフルオロメトキシ)フェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[3-(4-クロロ-2-(トリフルオロメチル)フェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[3-(4-クロロ-2-メトキシ-フェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[3-(2-クロロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[3-(3-クロロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[3-(4-クロロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[3-[2-メトキシ-4-(トリフルオロメトキシ)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[3-[4-クロロ-2-(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[3-(4-クロロ-2-メトキシ-フェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[3-(3,4-ジフルオロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[3-(4-フルオロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[3-(2-クロロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[3-(3-クロロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[3-(4-クロロフェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[3-[2,4-ビス(トリフルオロメチル)フェニル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[3-[2,4-ビス(トリフルオロメチル)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[3-[4-(トリフルオロメトキシ)フェニル]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
2-(3-メチル-1,2,4-オキサジアゾール-5-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;
[2-(3-メチル-1,2,4-オキサジアゾール-5-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エチル]カルバメート;
2-(5-メチル-1,2,4-オキサジアゾール-3-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エタノール;及び
[2-(5-メチル-1,2,4-オキサジアゾール-3-イル)-1-[3-[4-(トリフルオロメチル)フェニル]フェニル]エチル]カルバメート。 The compound of claim 1 selected from the group consisting of the following compounds, optical isomers, stereoisomers or pharmaceutically acceptable salts thereof:
1-[5-(4-chlorophenyl)-2-fluoro-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[5-(4-chlorophenyl)-2-fluoro-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl]carbamate;
(1R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
(1S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[2-methyl-5-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
1-[2-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[2-methyl-5-[4-(trifluoromethyl)phenyl]phenyl]ethyl]carbamate;
[1-[2-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[2-methyl-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
1-[2-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
[1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[2-chloro-5-[4-(trifluoromethyl)phenyl]phenyl]-2-(1,3,4-oxadiazol-2-yl)ethyl]carbamate;
2-(1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
2-(5-ethyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
2-(5-t-butyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl]acetate;
2-[2-methoxy-2-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl]-5-methyl-1,3,4-oxadiazole;
1-[3-(4-fluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[3-(3,4-difluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-[4-(trifluoromethoxy)phenyl]phenyl]ethanol;
1-[3-(2-methoxy-4-(trifluoromethoxy)phenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[3-(4-chloro-2-(trifluoromethyl)phenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[3-(4-chloro-2-methoxy-phenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[3-(2-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[3-(3-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[3-(4-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[3-[2-methoxy-4-(trifluoromethoxy)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[3-[4-chloro-2-(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[3-(4-chloro-2-methoxy-phenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[3-(3,4-difluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[3-(4-fluorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[3-(2-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[3-(3-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[3-(4-chlorophenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[3-[2,4-bis(trifluoromethyl)phenyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[3-[2,4-bis(trifluoromethyl)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[3-[4-(trifluoromethoxy)phenyl]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
2-(3-methyl-1,2,4-oxadiazol-5-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol;
[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl]carbamate;
2-(5-methyl-1,2,4-oxadiazol-3-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethanol; and [2-(5-methyl- 1,2,4-oxadiazol-3-yl)-1-[3-[4-(trifluoromethyl)phenyl]phenyl]ethyl]carbamate.
2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(2,2,3,3-テトラフルオロプロポキシ)フェニル]エタノール;
[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(2,2,3,3-テトラフルオロプロポキシ)フェニル]エチル]カルバメート;
1-[2-フルオロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[2-フルオロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[2-フルオロ-5-(2,2,2-トリフルオロエトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[2-フルオロ-5-(2,2,2-トリフルオロエトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(4,4,4-トリフルオロブトキシ)フェニル]エタノール;
[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(4,4,4-トリフルオロブトキシ)フェニル]エチル]カルバメート;
1-(5-ブトキシ-2-フルオロ-フェニル)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-(5-ブトキシ-2-フルオロ-フェニル)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[2-フルオロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[2-フルオロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[2-フルオロ-5-[3-(1-ピペリジル)プロポキシ]フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[5-[3-(ジメチルアミノ)プロポキシ]-2-フルオロ-フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-クロロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[5-[3-(ジメチルアミノ)プロポキシ]-2-フルオロ-フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-[2-クロロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
2-フルオロ-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(4,4,4-トリフルオロブトキシ)フェニル]エタノール;
2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(4,4,4-トリフルオロブトキシ)フェニル]プロパン-1-オール;
[2-フルオロ-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(4,4,4-トリフルオロブトキシ)フェニル]エチル]カルバメート;
[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)-1-[3-(4,4,4-トリフルオロブトキシ)フェニル]プロピル]カルバメート;
(1R)-1-[2-フルオロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;及び
(1S)-1-[2-フルオロ-5-(4,4,4-トリフルオロブトキシ)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール。 The compound of claim 1 selected from the group consisting of the following compounds, optical isomers, stereoisomers or pharmaceutically acceptable salts thereof:
2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(2,2,3,3-tetrafluoropropoxy)phenyl]ethanol;
[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(2,2,3,3-tetrafluoropropoxy)phenyl]ethyl]carbamate;
1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[2-fluoro-5-(2,2,2-trifluoroethoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[2-fluoro-5-(2,2,2-trifluoroethoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethanol;
[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]carbamate;
1-(5-butoxy-2-fluoro-phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-(5-butoxy-2-fluoro-phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
[1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[2-fluoro-5-[3-(1-piperidyl)propoxy]phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[5-[3-(dimethylamino)propoxy]-2-fluoro-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[2-chloro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[5-[3-(dimethylamino)propoxy]-2-fluoro-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-[2-chloro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
2-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethanol;
2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]propan-1-ol;
[2-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]carbamate;
[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-[3-(4,4,4-trifluorobutoxy)phenyl]propyl]carbamate;
(1R)-1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol; and (1S)-1-[2-fluoro-5-(4,4,4-trifluorobutoxy)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol .
1-[2-フルオロ-5-(3,3,3-トリフルオロプロピル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[2-フルオロ-5-(3,3,3-トリフルオロプロピル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[2-フルオロ-5-(3,3,3-トリフルオロプロピル)フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
1-(2-フルオロ-5-プロピル-フェニル)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-(2-フルオロ-5-ペンチル-フェニル)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-(2-フルオロ-5-プロピル-フェニル)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
[1-(2-フルオロ-5-ペンチル-フェニル)-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;
1-[2-フルオロ-5-(4,4,4-トリフルオロブチル)フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-フルオロ-5-(5,5,5-トリフルオロペンチル)フェニル]-2-(1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-フルオロ-5-(4,4,4-トリフルオロブチル)-フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
1-[2-フルオロ-5-(5,5,5-トリフルオロペンチル)-フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エタノール;
[1-[2-フルオロ-5-(4,4,4-トリフルオロブチル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート;及び
[1-[2-フルオロ-5-(5,5,5-トリフルオロペンチル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート。 The compound of claim 1 selected from the group consisting of the following compounds, optical isomers, stereoisomers or pharmaceutically acceptable salts thereof:
1-[2-fluoro-5-(3,3,3-trifluoropropyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[2-fluoro-5-(3,3,3-trifluoropropyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[2-fluoro-5-(3,3,3-trifluoropropyl)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
1-(2-fluoro-5-propyl-phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-(2-fluoro-5-pentyl-phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-(2-fluoro-5-propyl-phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
[1-(2-fluoro-5-pentyl-phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate;
1-[2-fluoro-5-(4,4,4-trifluorobutyl)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
1-[2-fluoro-5-(5,5,5-trifluoropentyl)phenyl]-2-(1,3,4-oxadiazol-2-yl)ethanol;
1-[2-fluoro-5-(4,4,4-trifluorobutyl)-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
1-[2-fluoro-5-(5,5,5-trifluoropentyl)-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol;
[1-[2-fluoro-5-(4,4,4-trifluorobutyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate; and [1-[2-fluoro-5-(5,5,5-trifluoropentyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate.
4-フルオロ-3-[1-ヒドロキシ-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]-N-(3,3,3-トリフルオロプロピル)ベンズアミド;及び
[1-[2-フルオロ-5-(3,3,3-トリフルオロプロピルカルバモイル)フェニル]-2-(5-メチル-1,3,4-オキサジアゾール-2-イル)エチル]カルバメート。 The compound of claim 1 selected from the group consisting of the following compounds, optical isomers, stereoisomers or pharmaceutically acceptable salts thereof:
4-fluoro-3-[1-hydroxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-N-(3,3,3-trifluoropropyl)benzamide; and [1-[2-fluoro-5-(3,3,3-trifluoropropylcarbamoyl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0113956 | 2018-09-21 | ||
KR20180113956 | 2018-09-21 | ||
PCT/KR2019/012257 WO2020060299A1 (en) | 2018-09-21 | 2019-09-20 | Compound containing oxadiazole, and pharmaceutical composition containing same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022503775A JP2022503775A (en) | 2022-01-12 |
JPWO2020060299A5 true JPWO2020060299A5 (en) | 2022-09-22 |
JP7430175B2 JP7430175B2 (en) | 2024-02-09 |
Family
ID=69887571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021516367A Active JP7430175B2 (en) | 2018-09-21 | 2019-09-20 | Compounds containing oxadiazole and pharmaceutical compositions containing the same |
Country Status (15)
Country | Link |
---|---|
US (3) | US11053208B2 (en) |
EP (1) | EP3854788A4 (en) |
JP (1) | JP7430175B2 (en) |
KR (1) | KR20210047889A (en) |
CN (1) | CN113272285B (en) |
AR (1) | AR118413A1 (en) |
AU (1) | AU2019341357B2 (en) |
BR (1) | BR112021005269A2 (en) |
CA (1) | CA3112700A1 (en) |
CL (1) | CL2021000618A1 (en) |
IL (1) | IL281553A (en) |
MX (1) | MX2021003204A (en) |
TW (1) | TWI826531B (en) |
WO (1) | WO2020060299A1 (en) |
ZA (1) | ZA202101520B (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US21121A (en) | 1858-08-10 | Appabattjs for purifying gas | ||
ZA803250B (en) | 1979-06-01 | 1982-01-27 | Wellcome Found | Substituded aromatic compounds |
GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
KR0162036B1 (en) | 1996-05-31 | 1998-12-01 | 추호석 | Motor control method and device in a stacker crane |
AU740813B2 (en) * | 1998-07-08 | 2001-11-15 | Monash University | Pharmaceutical agents |
UA78211C2 (en) | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
WO2006017409A2 (en) * | 2004-08-03 | 2006-02-16 | Merck & Co., Inc. | 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
CA2658887C (en) * | 2006-07-28 | 2016-08-23 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
PL2239253T3 (en) | 2008-02-06 | 2013-11-29 | Daiichi Sankyo Co Ltd | Novel phenylpyrrole derivative |
CN102725287B (en) | 2009-12-28 | 2015-07-01 | 一般社团法人创药分子谷项目支援机构 | 1,3,4-oxadiazole-2-carboxamide compound |
KR101713453B1 (en) * | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 inhibitors and related compositions and methods |
WO2017060488A1 (en) * | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
-
2019
- 2019-09-19 TW TW108133837A patent/TWI826531B/en active
- 2019-09-20 EP EP19863530.2A patent/EP3854788A4/en active Pending
- 2019-09-20 CA CA3112700A patent/CA3112700A1/en active Pending
- 2019-09-20 JP JP2021516367A patent/JP7430175B2/en active Active
- 2019-09-20 US US16/613,659 patent/US11053208B2/en active Active
- 2019-09-20 MX MX2021003204A patent/MX2021003204A/en unknown
- 2019-09-20 AU AU2019341357A patent/AU2019341357B2/en active Active
- 2019-09-20 AR ARP190102667A patent/AR118413A1/en unknown
- 2019-09-20 BR BR112021005269-0A patent/BR112021005269A2/en unknown
- 2019-09-20 KR KR1020217007242A patent/KR20210047889A/en not_active Application Discontinuation
- 2019-09-20 WO PCT/KR2019/012257 patent/WO2020060299A1/en active Application Filing
- 2019-09-20 CN CN201980076515.0A patent/CN113272285B/en active Active
-
2021
- 2021-03-05 ZA ZA2021/01520A patent/ZA202101520B/en unknown
- 2021-03-12 CL CL2021000618A patent/CL2021000618A1/en unknown
- 2021-03-16 IL IL281553A patent/IL281553A/en unknown
- 2021-05-24 US US17/327,928 patent/US11603358B2/en active Active
-
2023
- 2023-01-18 US US18/155,924 patent/US20230150955A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008523115A5 (en) | ||
RU2010125624A (en) | NEW CYCLIC HYDROCARBON COMPOUNDS FOR TREATMENT OF DISEASES | |
JP2006077019A5 (en) | ||
JP2008521827A5 (en) | ||
JP2014520809A5 (en) | ||
RU2009102278A (en) | S1P RECEPTOR MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
RU2006105639A (en) | NEW AMINOBENZOPHENONE DERIVATIVES | |
RU2012132692A (en) | NEW S-NITROSOGLUTATHYNE REDUCTASE INHIBITORS | |
JP2009506039A5 (en) | ||
JP2005536475A5 (en) | ||
BRPI0507506A (en) | compounds | |
HRP20100225T1 (en) | Triazole substituted aminobenzophenone compounds | |
JP2014502979A5 (en) | ||
JP2007502806A5 (en) | ||
RU2002122100A (en) | New connections | |
JP2004502670A5 (en) | ||
JP2009518421A5 (en) | ||
JP2011529037A5 (en) | ||
RU2015101210A (en) | THIOPHENE DERIVATIVES USED FOR TREATMENT OF DIABETES | |
JP2005506308A5 (en) | ||
RU2008127253A (en) | 1,1,3-TRIOXO-1,2,5-THIADIAZOLIDINES AND THEIR APPLICATION AS PTFASE INHIBITORS | |
HRP20200606T1 (en) | Phenyl derivatives as cannabinoid receptor 2 agonists | |
RU2012122056A (en) | DIAcylglycerol-O-Acyl Transferase Enzyme Inhibitors Type 1 | |
RU2015102610A (en) | TRIAZOLE COMPOUNDS AS ANTI-VIRAL DRUGS | |
JP2013544811A5 (en) |